Semaglutide reduces risk of kidney disease deaths by > 20% (Bloomberg)
- May 24, 2024
- 1 min read
Updated: Jun 24, 2024
As the clinic director, I’m thrilled to share some groundbreaking news that could revolutionize the treatment of kidney disease related to diabetes. A recent study published in the New England Journal of Medicine has revealed that Novo Nordisk’s diabetes drug, Ozempic/Semaglutide, significantly reduces the risk of death in patients with diabetic kidney disease.
This is a monumental discovery, as it offers hope and a new avenue for managing a condition that affects so many lives.
Here are the key takeaways from the study:
Reduced Mortality Risk: Patients taking Ozempic were one-fifth less likely to die from any cause compared to those on a placebo1.
Comprehensive Benefits: The drug also reduced the risk of various health outcomes linked to kidney and heart disease by 24%.
Expanding Treatment Horizons: Ozempic’s success in this trial suggests it could be a game-changer for treating cardio-kidney-metabolic syndrome, a cluster of conditions often associated with obesity.
This study not only underscores the close relationship between kidney disease, cardiovascular disease, and diabetes but also highlights the potential of Semaglutide to improve patient outcomes on top of existing treatments for diabetes, high blood pressure, and high cholesterol.
It’s an exciting time for healthcare professionals and patients alike, as we continue to explore the full potential of this medication in combating such a prevalent health issue.
Stay tuned for more updates on this promising development!
Give us a call at 253-340-2270 to help you on your path to better health and weight loss!
Full article here: msn.com
Pacific Northwest Medical Group
6622 112th ST E, Puyallup WA 98373
253-340-2270
Book a FREE consult now <- Click There!
